Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

2.50
Hdl Handle:
http://hdl.handle.net/10033/14575
Title:
Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.
Authors:
Reljic, R; Clark, S O; Williams, A; Falero-Diaz, G; Singh, M; Challacombe, S; Marsh, P D; Ivanyi, J
Abstract:
Intranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.
Citation:
Clin. Exp. Immunol. 2006, 143(3):467-73
Issue Date:
1-Mar-2006
URI:
http://hdl.handle.net/10033/14575
DOI:
10.1111/j.1365-2249.2006.03012.x
PubMed ID:
16487246
Type:
Article
Language:
en
ISSN:
0009-9104
Appears in Collections:
publications of the research group genomeanalytics (GMAK)

Full metadata record

DC FieldValue Language
dc.contributor.authorReljic, R-
dc.contributor.authorClark, S O-
dc.contributor.authorWilliams, A-
dc.contributor.authorFalero-Diaz, G-
dc.contributor.authorSingh, M-
dc.contributor.authorChallacombe, S-
dc.contributor.authorMarsh, P D-
dc.contributor.authorIvanyi, J-
dc.date.accessioned2007-11-15T09:34:37Z-
dc.date.available2007-11-15T09:34:37Z-
dc.date.issued2006-03-01-
dc.identifier.citationClin. Exp. Immunol. 2006, 143(3):467-73en
dc.identifier.issn0009-9104-
dc.identifier.pmid16487246-
dc.identifier.doi10.1111/j.1365-2249.2006.03012.x-
dc.identifier.urihttp://hdl.handle.net/10033/14575-
dc.description.abstractIntranasal inoculation of mice with monoclonal IgA against the alpha-crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short-term, we investigated if it could be extended by inoculation of IFNgamma 3 days before infection, and further co-inoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNgamma alone (i.e. 17-fold, from 4.2 x 10(7) to 2.5 x 10(6) CFU, P = 0.006), accompanied also by lower granulomatous infiltration of the lungs. IFNgamma added prior to infection of mouse peritoneal macrophages with IgA-opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFalpha production and a 2-3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNgamma and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.en
dc.format.extent5847539 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.titleIntranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.